期刊文献+

诺和锐30和诺和灵30R治疗老年2型糖尿病的对比研究 被引量:1

Nokh sharp 30 works 30R treatment old age 2 diabetes contrast research
原文传递
导出
摘要 目的:比较诺和锐30和诺和灵30R治疗老年2型糖尿病(T2DM)患者的疗效和安全性.方法:将口服降血糖药物血糖控制不佳的老年2型糖尿病96例患者,随机分为诺和锐30治疗组和诺和灵30R治疗组各48例,采用每日早、晚餐前两次皮下注射方案,观察两组患者7个时点血糖、糖化血红蛋白(HbA1C)、低血糖事件及其他不良事件的差异.结果:治疗后平均FBG、2hPG和HbA1c的变化两组间治疗后比较差异无显著性*P〉0.01 两组间低血糖事件发生率比较差异有显著性(P〈0.01).满意度比较差异具有显著性 P〈0.01.结论:对血糖控制不佳的老年糖尿病患者,和锐30和诺和灵30R均可安全有效地降低血糖,诺和锐30控制餐后血糖更具优势,低血糖事件发生率较低,满意度高. Objective: Sharp 30 works the 30R treatment old age 2 diabetes (T2DM) patient's curative effect compared with Nokh with Nokh and the security. Methods: Will take orally will fall the blood sugar medicine blood sugar control not good old age 2 diabetes 96 example patients, will divide into the Nokh sharp 30 treatment group to work stochastically 30R treatment group each 48 examples with Nokh,will use every day early, the supper first two hypodermic iniection plan,will observe two group of patient 7 point in time blood sugars,the saechariiication hemoglobin (HbAIC), the hypoglycemia event and other not good event difference. Results:After after the treatment average FBG, 2hPG and the HbAlc change during two groups treats comparison difference non-- significance P〉0.01 ; Two group of hypoglycemia event formation rate comparison difference has the significance (P〈0.01). The degree of satisfaction comparison difference has significance P〈0.01. Conclusion:To the blood sugar control not good old age diabetic, with sharp 30 works 30R with Nokh to be possible effectively to reduce the blood sugar safely,after the Nokh sharp 30 control meal blood sugar has the superiority, the hypoglycemia event formation rate is low, degree of satisfaction high.
出处 《按摩与康复医学》 2010年第36期16-17,共2页 Chinese Manipulation and Rehabilitation Medicine
关键词 老年人 2 型糖尿病 诺和锐 30 诺和灵 30R 血糖 The senior citizen 2 diabetes Nokh sharp 30 Nokh works 30R The blood sugar
  • 相关文献

参考文献4

二级参考文献12

  • 1李春元.餐后高血糖的临床意义及治疗进展[J].世界临床药物,2005,26(3):178-181. 被引量:35
  • 2蔡乐,朱珠,王强,刘新月.胰岛素类似物与新型降糖激素类药物[J].中国新药杂志,2007,16(6):432-437. 被引量:26
  • 3Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemie control withbiphasie insulin aspart retationto biphasie insulin lispro and hiphasie human'insulin inpatients with type 2 diabetes[J]. Diabetes Care, 2002, 25 : 883-888.
  • 4Mcsorley PT, Bell PM, Jacobsen LV, et al.Twice-daily bi-phasic insulin aspart 30 versusbiphasic hunm an insulin 30: a double-blind cross-over study in adults, with type 2diabetes mellitus [J].Clin Ther, 2002, 24 : 530-539.
  • 5[1]Jovanovie L.Rationale for prevention and treatment of postprandial glucose-mediated toxicity[J].Endocrinologist,1999,9:87
  • 6[2]Mesorleg PT,Bell PMJacobsen LV,et al.Twiee-dailg biphasic in sulin aspart 30 versus biphasie human insulin 30:a double-blind cross over study in adults with type 2 diabetes mellitus.Clin Ther,2002,24(4):530-539
  • 7[3]Boehm BO,Vaz JA,Brondsted Let al.Long-term efficacy and safety of biphasie insulin aspart in patients with type 2 diabetes.Eur Inter Med,2004(15):496-502
  • 8[4]Lindholm A,McEwen J,Riss AP.Improved postprandial gly-eaemic control with insulin aspart-arandomized double-blinde cross over trial in type ldiabetes mellitus.Diabetes Care,1999,22:801-805
  • 9[5]Rosenfalck A,Thorsby P,Rjems L,et al.Improved postprandial gly eaemic controls with insulin Aspart in type 2 diabetic patients treated with insulin.Acta Diabetologia,2000,37:41-46
  • 10[6]Jacobsen LV,Sogard B,Riis.A.Pharmacokinetics and pharmacody namics of a premixed formulation of soluble and protamine retard ed insulin aspart.Eur Clin Pharmacol,2000,56:399-403

共引文献12

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部